ZA201508642B - Malaria vaccine - Google Patents
Malaria vaccineInfo
- Publication number
- ZA201508642B ZA201508642B ZA2015/08642A ZA201508642A ZA201508642B ZA 201508642 B ZA201508642 B ZA 201508642B ZA 2015/08642 A ZA2015/08642 A ZA 2015/08642A ZA 201508642 A ZA201508642 A ZA 201508642A ZA 201508642 B ZA201508642 B ZA 201508642B
- Authority
- ZA
- South Africa
- Prior art keywords
- malaria vaccine
- malaria
- vaccine
- Prior art date
Links
- 229940124735 malaria vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/193—Equine encephalomyelitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361830436P | 2013-06-03 | 2013-06-03 | |
| US201361906583P | 2013-11-20 | 2013-11-20 | |
| PCT/JP2014/065166 WO2014196648A1 (en) | 2013-06-03 | 2014-06-02 | Malaria vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201508642B true ZA201508642B (en) | 2022-03-30 |
Family
ID=52005658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/08642A ZA201508642B (en) | 2013-06-03 | 2015-11-24 | Malaria vaccine |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9512190B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3004348B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6734651B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102494564B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105431535A (cg-RX-API-DMAC7.html) |
| AP (1) | AP2015008926A0 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014275772B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015030229B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2913832C (cg-RX-API-DMAC7.html) |
| IL (1) | IL242656B (cg-RX-API-DMAC7.html) |
| MX (1) | MX386234B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2702163C2 (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201709917VA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI687442B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014196648A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201508642B (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013221187B9 (en) | 2012-02-16 | 2018-01-04 | Vlp Therapeutics, Inc. | Virus like particle composition |
| TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| WO2016021209A1 (en) | 2014-08-08 | 2016-02-11 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein e3 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| EP3191589B1 (en) | 2014-09-11 | 2025-11-26 | VLP Therapeutics, Inc. | Flavivirus virus like particle |
| US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| US9968665B2 (en) * | 2015-09-16 | 2018-05-15 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| SG11201909265QA (en) | 2017-04-19 | 2019-11-28 | Inst Res Biomedicine | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to |
| CN110612116A (zh) | 2017-05-08 | 2019-12-24 | 磨石肿瘤生物技术公司 | 甲病毒新抗原载体 |
| KR102823029B1 (ko) | 2017-12-20 | 2025-06-20 | 브이엘피 테라퓨틱스 인코포레이티드 | 알파바이러스 레플리콘 입자 |
| AU2019205330B2 (en) | 2018-01-04 | 2025-09-11 | Iconic Therapeutics Llc | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| TW202523847A (zh) | 2019-05-30 | 2025-06-16 | 美商磨石生物公司 | 經修飾之腺病毒 |
| US12280102B2 (en) | 2020-04-17 | 2025-04-22 | Vlp Therapeutics, Inc. | Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains |
| CN115552009A (zh) | 2020-04-30 | 2022-12-30 | Vlp治疗公司 | 细胞因子免疫疗法 |
| EP4192496A4 (en) | 2020-08-06 | 2025-01-01 | Gritstone bio, Inc. | MULTIEPITOP VACCINE CASSETTES |
| CN118510792A (zh) * | 2021-11-22 | 2024-08-16 | 诺瓦瓦克斯公司 | 用于治疗和预防疟疾的方法和组合物 |
| WO2025064770A2 (en) * | 2023-09-20 | 2025-03-27 | La Jolla Institute of Immunology | Alphavirus t cell epitopes, megapools and uses thereof |
| WO2025084276A1 (ja) * | 2023-10-16 | 2025-04-24 | Ｃｙｎ－Ｋバイオ株式会社 | 肥満の処置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100251505B1 (ko) * | 1991-11-16 | 2000-05-01 | 장 스테판느 | 말라리아원충으로부터의 cs 및 hbsag 사이의 혼성 단백질(hybrid protein between cs from plasmodium and hbsag) |
| AU2003295470A1 (en) | 2002-11-13 | 2004-06-03 | The United States Of America As Represented By The Secretary Of The Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| US20080131461A1 (en) * | 2004-10-14 | 2008-06-05 | Crucell Holland B.V. | Malaria Prime/Boost Vaccines |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| AU2007291936B2 (en) * | 2006-08-30 | 2012-09-27 | Artes Biotechnology Gmbh | Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
| CN102317308A (zh) * | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| WO2011022002A1 (en) * | 2009-08-18 | 2011-02-24 | The Rockefeller University | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
| EP2477650B8 (en) * | 2009-09-18 | 2019-10-09 | FRAUNHOFER USA Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
| WO2012006180A1 (en) * | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| WO2012023995A1 (en) * | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
| US9487563B2 (en) * | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
| AU2013221187B9 (en) * | 2012-02-16 | 2018-01-04 | Vlp Therapeutics, Inc. | Virus like particle composition |
| WO2016021209A1 (en) | 2014-08-08 | 2016-02-11 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein e3 |
-
2014
- 2014-06-02 JP JP2015558676A patent/JP6734651B2/ja active Active
- 2014-06-02 MX MX2015016627A patent/MX386234B/es unknown
- 2014-06-02 SG SG10201709917VA patent/SG10201709917VA/en unknown
- 2014-06-02 AP AP2015008926A patent/AP2015008926A0/xx unknown
- 2014-06-02 KR KR1020217029655A patent/KR102494564B1/ko active Active
- 2014-06-02 EP EP14807026.1A patent/EP3004348B1/en active Active
- 2014-06-02 KR KR1020157035411A patent/KR20160016856A/ko not_active Ceased
- 2014-06-02 IL IL242656A patent/IL242656B/en unknown
- 2014-06-02 WO PCT/JP2014/065166 patent/WO2014196648A1/en not_active Ceased
- 2014-06-02 AU AU2014275772A patent/AU2014275772B2/en not_active Ceased
- 2014-06-02 RU RU2015155821A patent/RU2702163C2/ru active
- 2014-06-02 SG SG11201509614SA patent/SG11201509614SA/en unknown
- 2014-06-02 CA CA2913832A patent/CA2913832C/en active Active
- 2014-06-02 CN CN201480043750.5A patent/CN105431535A/zh active Pending
- 2014-06-02 BR BR112015030229-7A patent/BR112015030229B1/pt not_active IP Right Cessation
- 2014-06-03 TW TW103119188A patent/TWI687442B/zh active
- 2014-06-03 US US14/294,968 patent/US9512190B2/en active Active
-
2015
- 2015-11-24 ZA ZA2015/08642A patent/ZA201508642B/en unknown
-
2016
- 2016-10-21 US US15/299,859 patent/US20170035871A1/en not_active Abandoned
-
2019
- 2019-03-28 US US16/367,374 patent/US20190351041A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276210B1 (en) | Mers-cov vaccine | |
| IL279395A (en) | A vaccine | |
| ZA201508642B (en) | Malaria vaccine | |
| GB201318084D0 (en) | Malaria vaccination | |
| PL3077519T3 (pl) | Szczepionki CMV | |
| GB201315946D0 (en) | Oncology vaccine | |
| GB201321242D0 (en) | Immunogenic compound | |
| SI2968493T1 (sl) | Izboljšana poksvirusna cepiva | |
| GB201301085D0 (en) | Glycoconjugate Vaccine | |
| PL2944730T3 (pl) | Miska ustępowa sedesu | |
| PL2958935T3 (pl) | Szczepionka | |
| AP2015008615A0 (en) | Vaccines against pregnancy-associated malaria | |
| EP3043815A4 (en) | Malaria vaccine | |
| GB2547494B (en) | Monovalent H5 vaccine | |
| GB201301119D0 (en) | Viral vaccines | |
| GB201320646D0 (en) | Vaccine | |
| GB201315556D0 (en) | Vaccine | |
| GB201320421D0 (en) | Conjugated vaccine | |
| GB201314063D0 (en) | Virus | |
| AU2013901139A0 (en) | Cultured malaria vaccine | |
| GB201306812D0 (en) | Virus | |
| GB201310280D0 (en) | Odontalgic preparation | |
| AU353306S (en) | Top | |
| AU353345S (en) | Top | |
| AU2013903204A0 (en) | Plasmodium Antigens |